Glenmark Debuts Favipiravir For COVID-19 In India
Poised For Scale-Up Using In-House Capabilities
Executive Summary
Glenmark has received the go-ahead in India for and launched its low-priced favipiravir product for mild to moderate COVID-19 under an accelerated approval process. While the firm says trial findings are in line with global data, with patients showing clinical improvements within the first seven days, social media is abuzz, with some physicians seeking greater clarity.
You may also be interested in...
Remdesivir Rivals Hit Indian Market
Gilead licensees Hetero and Cipla introduce remdesivir, the antiviral seen as a potential treatment for COVID-19, in India. Pricing plans will be closely watched and supplies in the country are expected to stabilize soon, possibly turning to a surplus situation in several months.
Coronavirus Update: Moderna Progesses To Phase II, Russia Approves Homegrown Antiviral
Moderna maintains its lightning pace, but questions about its Phase III trial design remain.
Coronavirus Update: Sinovac Gets $15m Towards CoronaVac Phase II, Remdesivir Early Access In UK
Multiple vaccine and drug developers across the world report progress and partnerships amid volatility in their shares.